ROSUVASTATIN 10mg. IP + CLOPIDOGREL 75mg. IP + ASPIRIN 75mg. IP

Belongs to a group of antihyperlipidemic and antiplatelets that treat heart attack, myocardial infarction, angina, and stroke. A potent antiplatelet agent reduces the risk for thrombotic events in patients with atherothrombotic diseases. (Sung-Doo Kim, 2009) Corrects the levels of fatty substances, and aids stop blockages from forming in arteries. Produces substantial reductions in low-density lipoprotein cholesterol. A promising new medication for the treatment of dyslipidemias. (Olsson, 24) A valuable addition to the statin drug class. (Cheng-Lai, 2003) Facilitates efficient management of patients with dyslipidemia. (Kathleen M Fox, 2007) A well-tolerated and effective drug that exerts a good safety profile in hypercholesterolemic patients. (Charles J Glueck, 2006) Lessens the risk of cardiovascular events and stabilizes atherosclerosis. (Toth, 2014) More efficacious in improving the lipid profile of patients with hypercholesterolemia than atorvastatin, simvastatin, and pravastatin. (Peter H Jones, 2004) An effective treatment for reducing low-density lipoprotein cholesterol levels than the other statins in a population of elderly patients. (Carolyn R Harley, 2007) Lowers the risk of cardiovascular disease and coronary events like heart attack, stroke, and heart-related chest pain.